Related Articles
Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma
Molecular targeted therapies for cancer: Sorafenib monotherapy and its combination with other therapies (Review)
Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up‑regulation of TNF‑related apoptosis‑inducing ligand
Sulforaphane blocks hypoxia-mediated resistance to TRAIL-induced tumor cell death